Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia : Experts' Opinion using a Delphi Approach
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability.
OBJECTIVE: To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique.
METHOD: A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%).
RESULTS: Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data.
CONCLUSION: These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Current neuropharmacology - 21(2023), 11 vom: 21., Seite 2206-2216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dell'Osso, Bernardo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antipsychotic Agents |
|---|
| Anmerkungen: |
Date Completed 11.09.2023 Date Revised 02.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1570159X21666230719162023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359696023 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359696023 | ||
| 003 | DE-627 | ||
| 005 | 20240302232245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1570159X21666230719162023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM359696023 | ||
| 035 | |a (NLM)37469149 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dell'Osso, Bernardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia |b Experts' Opinion using a Delphi Approach |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.09.2023 | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability | ||
| 520 | |a OBJECTIVE: To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique | ||
| 520 | |a METHOD: A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%) | ||
| 520 | |a RESULTS: Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data | ||
| 520 | |a CONCLUSION: These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Schizophrenia | |
| 650 | 4 | |a cariprazine | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a negative symptoms | |
| 650 | 4 | |a positive symptoms | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a switch | |
| 650 | 7 | |a cariprazine |2 NLM | |
| 650 | 7 | |a F6RJL8B278 |2 NLM | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 700 | 1 | |a Bellomo, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Maria Conca, Andreas Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Salvi, Virginio |e verfasserin |4 aut | |
| 700 | 1 | |a Siracusano, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Zaffora, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a De Berardis, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Di Giannantonio, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current neuropharmacology |d 2004 |g 21(2023), 11 vom: 21., Seite 2206-2216 |w (DE-627)NLM175794456 |x 1875-6190 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:11 |g day:21 |g pages:2206-2216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1570159X21666230719162023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 11 |b 21 |h 2206-2216 | ||